Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 124
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Title
Phase
Protocol IDs
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
Phase III, Phase II
20050113
NCT00243685
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Phase III, Phase II
WIRB 20060042
NCT00443196
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Phase III
DUMC03
DUKE UNIVERSITY MEDICAL CENTER, CLINICAL STUDY PROTOCOL, NCT00090610
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Phase III
CEPO906A2303
NCT00262990
OVATURE (OVArian TUmor REsponse) Study: A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Phase III
NV06-0039
NCT00382811
A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma (OCEANS)
Phase III
AVF4095g
NCT00434642
Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients with Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
Phase III
GOG-0213
GOG-0213, NCT00565851
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
Phase III
KTN32313R
NCT00477282
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation
Phase II, Phase I
FHCRC-1803.00
5606, NCT00068718
Ixabepilone and Liposomal Doxorubicin in Treating Women With Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer
Phase II, Phase I
AECM-0504007857
NCI-7229, 7229, NCT00182767
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute